Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.577,37
1,09%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MaxCyte Inc (MXCT) MaxCyte Inc (MXCT) Notizie

MaxCyte Inc

MXCT
3,77
-0,06 (-1,57%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/4/202414:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02/4/202414:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
12/3/202421:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
05/3/202422:15EDGAR2Form 8-K - Current report
04/3/202423:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202422:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
26/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202414:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
01/2/202422:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202414:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
26/1/202422:45EDGAR2Form 8-K - Current report
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202414:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
08/1/202422:15EDGAR2Form 8-K - Current report
08/1/202422:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
04/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02/1/202408:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
28/12/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:30EDGAR2Form 8-K - Current report
11/12/202322:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
06/12/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:32EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/11/202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202314:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
08/11/202323:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:12EDGAR2Form 8-K - Current report
08/11/202322:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
06/11/202322:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
04/10/202322:14EDGAR2Form 8-K - Current report
04/10/202322:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
06/9/202314:05GLOBEMaxCyte Appoints Ali Soleymannezhad as Executive Vice..
05/9/202314:05GLOBEMaxCyte to Participate in Baird Global Healthcare Conference
30/8/202323:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:16EDGAR2Form 8-K - Current report
09/8/202322:05GLOBEMaxCyte Reports Second Quarter and Half-Year 2023 Financial..
01/8/202314:05GLOBEMaxCyte Signs Strategic Platform License with Prime Medicine..
28/7/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202314:05GLOBEMaxCyte to Report Second Quarter 2023 Financial Results on..
13/7/202300:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202322:51EDGAR2Form 144 - Report of proposed sale of securities
10/7/202314:05GLOBEMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform..
06/7/202314:05GLOBEMaxCyte Signs Strategic Platform License with Lyell..
Apertura: 3,95 Min: 3,74 Max: 3,95
Chiusura: 3,83

La tua Cronologia

NASDAQ
MXCT
MaxCyte
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network